- Home
- DAWN vs KRP Comparison
DAWN vs KRP Comparison
Compare DAWN & KRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- KRP
- Stock Information
- Founded
- DAWN 2018
- KRP 2013
- Country
- DAWN United States
- KRP United States
- Employees
- DAWN N/A
- KRP N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- KRP Oil & Gas Production
- Sector
- DAWN Health Care
- KRP Energy
- Exchange
- DAWN Nasdaq
- KRP Nasdaq
- Market Cap
- DAWN 1.3B
- KRP 1.3B
- IPO Year
- DAWN 2021
- KRP 2017
- Fundamental
- Price
- DAWN $12.24
- KRP $15.95
- Analyst Decision
- DAWN Strong Buy
- KRP Buy
- Analyst Count
- DAWN 7
- KRP 4
- Target Price
- DAWN $36.33
- KRP $19.50
- AVG Volume (30 Days)
- DAWN 1.1M
- KRP 889.9K
- Earning Date
- DAWN 02-24-2025
- KRP 02-27-2025
- Dividend Yield
- DAWN N/A
- KRP 10.97%
- EPS Growth
- DAWN N/A
- KRP N/A
- EPS
- DAWN N/A
- KRP 0.52
- Revenue
- DAWN $101,953,000.00
- KRP $325,011,605.00
- Revenue This Year
- DAWN N/A
- KRP $17.86
- Revenue Next Year
- DAWN $35.22
- KRP $8.62
- P/E Ratio
- DAWN N/A
- KRP $30.68
- Revenue Growth
- DAWN N/A
- KRP 30.47
- 52 Week Low
- DAWN $11.13
- KRP $14.57
- 52 Week High
- DAWN $18.07
- KRP $17.07
- Technical
- Relative Strength Index (RSI)
- DAWN 45.74
- KRP 50.40
- Support Level
- DAWN $11.13
- KRP $15.87
- Resistance Level
- DAWN $12.74
- KRP $16.08
- Average True Range (ATR)
- DAWN 0.51
- KRP 0.27
- MACD
- DAWN 0.06
- KRP 0.00
- Stochastic Oscillator
- DAWN 51.15
- KRP 51.87
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas, and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.